Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
← catalyst calendarNCT05445323 · readout ≤ 1,138 d
Sponsored by Lexeo Therapeutics (industry) · LXEO — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
8actual
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-24 | actual | When the study began enrolling |
| Primary completion | Sep 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Friedreich Ataxia
- Cardiomyopathy, Secondary
Interventions
- Genetic: Low dose LX2006
- Genetic: Mid Dose LX2006
- Genetic: High Dose LX2006
Primary outcome
what the primary-completion date above is the date OFTreatment-emergent adverse events (TEAEs) and Treatment-emergent serious events (TESAEs)
measured Change from baseline to end of year 5 post dose
Publications
- PMID 42307907 — linked by the registry
- PMID 40739200 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LXEO's whole pipeline · Catalyst calendar · Every registered study · What changed